(Bloomberg) -- Annovis Bio Inc., a clinical-stage biotechnology company, announced a proposed public offering of stock and warrants on Tuesday to fund the late-stage clinical trial of its lead drug candidate for Alzheimer's disease. The size and terms of the offering were not disclosed.
The Malvern, Pennsylvania-based company said it intends to use the net proceeds for the continued clinical development of its lead compound, buntanetap, which is currently in a Phase 3 study for Alzheimer's disease. Funds will also be used for working capital and general corporate purposes, according to the press release.
"The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering," the company stated in a filing. Canaccord Genuity is acting as the sole bookrunner for the offering.
This capital raise is critical for Annovis as it advances buntanetap, an oral therapy aimed at inhibiting the formation of multiple neurotoxic proteins. For investors, the offering introduces the potential for share dilution, a common occurrence for clinical-stage biotech firms that do not yet have recurring revenue from approved products. The success of the company hinges on the outcome of its expensive, late-stage trials, making access to capital markets a crucial lifeline.
Buntanetap represents Annovis's primary effort to tackle neurodegenerative diseases. The drug works by targeting the translation of several proteins known to be involved in diseases like Alzheimer's and Parkinson's, including amyloid beta, tau, and alpha-synuclein. This mechanism of action is distinct from many other Alzheimer's therapies that have focused on a single target.
The Alzheimer's drug landscape is intensely competitive, with large pharmaceutical companies like Eli Lilly and Co. and Biogen Inc. dominating the market with their approved antibody treatments. Annovis, with a market capitalization of around $100 million, is a much smaller player betting on a different scientific approach. A successful Phase 3 trial is the necessary next step to bring buntanetap closer to potential FDA approval and commercialization.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission in February 2024. While the announcement may create short-term pressure on Annovis's stock (NYSE: ANVS) due to dilution, the funds are essential for the company to reach its next major clinical milestone.
This article is for informational purposes only and does not constitute investment advice.
